Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 | P53350 | 1/20 | 0.51 |
| ▸ | S1PR1 | P21453 | 17/20 | 0.49 |
| ▸ | S1PR5 | Q9H228 | 14/20 | 0.47 |
| ▸ | S1PR3 | Q99500 | 9/20 | 0.47 |
| ▸ | S1PR4 | O95977 | 12/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1029129 | 0.85 | PLK1 (0.52) | PLK1S1PR1S1PR5S1PR3S1PR4 | |
| SCHEMBL5988215 | 0.84 | PLK1 (0.49) | PLK1S1PR1S1PR5S1PR3S1PR4 | |
| SCHEMBL3901410 | 0.83 | S1PR1 (0.49) | PLK1S1PR1S1PR5S1PR3S1PR4 | |
| SCHEMBL12956546 | 0.80 | S1PR1 (0.46) | PLK1S1PR1S1PR5S1PR3S1PR4 | |
| SCHEMBL2538238 | 0.78 | PLK1 (0.47) | PLK1S1PR1S1PR5S1PR3S1PR4 | |
| SCHEMBL3904435 | 0.78 | PLK1 (0.47) | PLK1S1PR1S1PR5S1PR3S1PR4 | |
| SCHEMBL8423071 | 0.77 | PLK1 (0.55) | PLK1S1PR1S1PR5S1PR3S1PR4 | |
| Ammonia Solution, Strong SCHEMBL4951074 | 0.76 | S1PR1 (0.58) | PLK1S1PR1S1PR5S1PR3S1PR4 | |
| SCHEMBL820778 | 0.75 | PLK1 (0.56) | PLK1S1PR1S1PR5S1PR3S1PR4 | |
| SCHEMBL10084286 | 0.74 | CYP2A6 (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120101124-A1 | 1,2,4-OXADIAZOL DERIVATIVES, THEIR PHARMACEUTICAL COMPOSITIONS AND THEIR USE AS SPHINGOSINE 1-PHOSPHATE 1 RECEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 2012-04-26 | — | — | US | disclosed |
| US-7358386-B2 | Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation | BAYER PHARMACEUTICALS CORPORATION (US) | 2008-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120101124-A1 | 1,2,4-OXADIAZOL DERIVATIVES, THEIR PHARMACEUTICAL COMPOSITIONS AND THEIR USE AS SPHINGOSINE 1-PHOSPHATE 1 RECEPTOR AGONISTS | S1PR1, S1PR3, S1PR2 | PLK1 631/4885S1PR1 1/4885S1PR5 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.